IGF1‐mediated HOXA13 overexpression promotes CRC metastasis through upregulating ACLY and IGF1R. Combination treatment of ETC‐1002 with the IGF1R inhibitor linsitinib significantly inhibits HOXA13‐mediated CRC metastasis. Here, IGF1R is linked to colorectal carcinoma.